title: [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
abstract: Withdrawal symptoms occurred in a male neonate after maternal use of venlafaxine for depression during pregnancy. The symptoms were restlessness, hypertonia, jitteriness, irritability and poor feeding. The diagnosis was confirmed by a temporary improvement after administration of a low dose (1 mg) of venlafaxine to the boy. Eventually the symptoms began to decline spontaneously, and ceased after 8 days. Exposure to venlafaxine and other antidepressants which inhibit serotonin reuptake during the third trimester of pregnancy carries the risk of a neonatal withdrawal syndrome.
authors.affiliation: Afd. Kindergeneeskunde, TweeSteden ziekenhuis, Postbus 90.107, 5000 LA Tilburg. rdmoor@tsz.nl
authors.forename: R A
authors.initials: RA
authors.lastname: de Moor
authors.forename: L
authors.initials: L
authors.lastname: Mourad
authors.forename: J
authors.initials: J
authors.lastname: ter Haar
authors.forename: A C
authors.initials: AC
authors.lastname: Egberts
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009357:Neonatal Abstinence Syndrome; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride